Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application - Hagens Berman
Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
TomaGold Announces Closing of First Tranche of Private Placement Featuring Strategic Investment from SIDEX and NQIM
CoTec Holdings Corp. Announces Partial Settlement and Amendment and Restatement of Convertible Loan Facilities
